No nukes in lymphoma treatment – Two innovative biotech drugs that target tumor cells for destruction by tiny radioactive particles are struggling in the marketplace, in part because cancer doctors are simply too specialized to make proper use of them. …
Every trend has its counterexamples, and the rush of venture funding into biotechnology is no exception.
VentureWire reports today (subscription required) on the case of Sequella, a small Rockville, Md., biotech working on new therapies for drug-resistant tuberculosis (whose bacterium …
Dollars may be sluicing into biotechnology via venture investments and acquisitions these days, but there’s still one place that private biotechs can’t seem to catch a break, and that’s in the public markets.
The latest casualty here is PTC Therapeutics, …
Now that AstraZeneca has made the bold — or impulsive — decision to snap up MedImmune for $15.6 billion in cash, one big question is whether the U.K. pharmaceutical giant has kicked Big Pharma’s appetite for biotech acquisitions into high …
Biotechnology and medical-device venture investment soared in the first quarter as funding for information technology and other sectors declined, according to data compiled by Ernst & Young and Dow Jones VentureOne.
Overall venture funding for U.S. companies rose 8% in …
Amgen’s anemia rollercoaster — Biotechnology titan Amgen may have dodged a bullet when a study released Thursday showed that its anemia drug Aranesp didn’t shorten the lives of patients, after several other studies had suggested the opposite. But its anemia …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
Amgen’s anemia rollercoaster — Biotechnology titan Amgen may …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
A second legislative fight for the biotech industry …
A second legislative fight for the biotech industry is shaping up in Washington over whether to give the Food and Drug Administration authority to approve “generic” versions of biotechnology drugs whose patents have expired.
Measures that would grant FDA that …
A long-awaited struggle over patent reform appears to be upon us, the Washington Post reports today (hat tip to the WSJ’s Health Blog). It pits the tech industry against pharmaceutical/biotech companies over intellectual property protections that, depending on where you …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
A long-awaited struggle over patent reform appears to …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
Venture investors’ interest in early-stage biotech companies may …
Venture investors’ interest in early-stage biotech companies may finally be starting to revive, nearly six years after the collapse of a biotech-stock bubble quashed appetites for the industry’s riskiest but often most innovative companies.
Biotech fundraising is certainly booming. The …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
Cautionary tales: An occasional look at events with …
[Editor's note: David Hamilton, a former Wall Street Journal reporter, has covered the biotech sector for years and we're delighted to have him as a contributor on news and trends in biotech, health and science (we've already run a …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
[Editor's note: David Hamilton, a former Wall …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
For what appears to be the first time, …
For what appears to be the first time, a major drug company has plunked down a significant equity investment in embryonic stem cells.
Earlier today, VentureWire reported (sub required) that Novocell, an early-stage San Diego biotech that aims to treat …
